Abstract
Abstract Introduction Hypertrophic cardiomyopathy (HCM) affects 20 million individuals globally, with increased risk of sudden death and heart failure. While cardiac myosin inhibitors show great promise as disease-specific treatment, current indications are for obstructive HCM. Obstruction is not always well characterized by echocardiography, and artificial intelligence (AI) might assist in the improving the underdiagnosis of left ventricular outflow tract (LVOT) obstruction. Methods We identified 2,693 patients with LVOT obstruction and 6,177 control patients matched by age, sex, and septal thickness. A deep learning model was trained on non-Doppler apical-4-chamber (A4C) B-mode echocardiographic videos to detect the presence of outflow obstruction identified later in the same study by spectral Doppler. Model performance was evaluated on held-out test sets from Cedars-Sinai Medical Center (CSMC) and from Stanford Healthcare (SHC). Results In a held-out test set of 6,034 videos from CSMC, our model demonstrated strong performance in detecting LVOT obstruction with an AUC of 0.865, sensitivity of 77.8%, and specificity of 79.8%. Performance was consistent across various patient subgroups, including those with hyperdynamic LV function, pre-existing valvular disease, and small LV cavity size. The model demonstrated generalizable performance in the SHC cohort with an AUC of 0.866. Conclusion In this study, we developed an AI model to detect LVOT obstruction from standard A4C echo videos, highlighting patients may benefit from more detailed cardiac workup for obstructive HCM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Ouyang reports support from the National Institutes of Health (R00HL157421, R01HL173487 and R01HL173526) and Alexion, and consulting or honoraria for lectures from EchoIQ, Ultromics, Pfizer, InVision, the Korean Society of Echocardiography, and the Japanese Society of Echocardiography. We gratefully acknowledge support from the Sarnoff Cardiovascular Research Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Boards at Cedars-Sinai Medical Center and Stanford Healthcare.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to update the author's funding sources.
Data Availability
Model weights will be publicly released on GitHub.
